Skip to main content
Oceanic Palliative Care Conference 2023
Times are shown in your local time zone GMT

Phase 1 dose-ranging study and development of a two-compartment model of vaporised cannabis in people with advanced cancer experiencing anorexia

Oral Presentation Concurrent Sessions

Oral Presentation - Concurrent Sessions

12:15 pm

14 September 2023

Level 4 - Room 4.5

Stream 3D | Concurrent Session | Clinical care

Presentation Streams

Clinical Care

Watch The Presentation

Presentation Description

Institution: University of Technology Sydney - NSW, Australia

Introduction: Vaporised medicinal cannabis has the potential to improve anorexia in people with advanced cancer however, pharmacokinetic studies are lacking. This Phase I study assessed the pharmacokinetics, safety and tolerability of vaporised botanical cannabis flower bud. 
Methods: In an advanced cancer population with anorexia, placebo/Bedrobinol® was vaporised three times a day, one hour before meals and escalated over seven days (average 0–6.96 mg delta-9-tetrahydrocannabinol (∆-9-THC)). Bloods were collected at pre-dose, 1, 5, 20, 40, 60 mins and 4 hours post dose. Safety was measured using a numerical rating scale (NRS), Patient Health Questionnaire (PHQ-9), Generalised Anxiety Disorder Assessment (GAD-7) and National Cancer Institute Common Terminology for Adverse Events (NCICTCAE).  Vaporiser tolerability was surveyed.
Results: Twelve participants (7 females; mean age: 66.6 years) completed the study. The dose-concentration relationship of vaporised ∆-9-THC followed standard first order pharmacokinetics, with an exponential increase between 16 and 32 mg and displayed linear kinetics on elimination. A dose-exposure relationship became relatively linear after 16 mg, with significant inter- but not intra-participant variability. A two-compartment pharmacokinetics model identified ∆-9-THC dose as a significant covariate for bioavailability. The NRS reported grade 3 “intoxicated” for 48 mg, with a general increase for “relaxed” and “drowsy”. There was a significant decrease (p<0.05) for PHQ-9 at Days 8 and 14 compared to baseline. NCICTCAE reported grade 3 hypertension on Day 1, 6 (n=2), 8 and 14 (n=1) and grade 4 constipation on Day 14 (n=1). Overall tolerability was 99.2%.
Conclusions: These findings provide robust pharmacokinetic parameters for vaporised ∆-9-THC to guide future research and is relatively safe and well tolerated at these doses for people with advanced cancer. 

Presenters

Authors

Authors

Dr Tina Naumovski - South West Sydney Clinical Campuses - Faculty of Medicine & Health, the University of New South Wales , Prof. Meera Agar - University of Technology Sydney

Please be advised this website collects and stores your cookies to improve your experience. By using this website, you agree to our use of cookies. For more information, please refer to our